A novel and potent Pb-212 alpha-particle therapy for NETs – Complete responses in mouse models to global clinical translation for NET patients

#3722

Introduction: A novel SSTR2 targeted peptide (VMT-alpha-NET) has been developed. Promising preclinical data have led to the initiation of multiple Phase 1 clinical trials in the United States for Pb-203 image-guided Pb-212 based alpha-particle therapy for NETs.

Aim(s): The Aim of the presentation is: (1) to highlight the tumor responses and tolerability of [212Pb]VMT-alpha-NETin preclinical models compared to other radionuclide therapies for NETs; (2) to illuminate the clinical trials that have been initiated for NETs in the United States; and (3) to describe activities related to global dissemination of the new Pb-212 and Pb-203 and Pb-212.

Materials and methods: Peptides were synthesized and radiolabelled by published methods. Preclinically, single or fractionated doses of agents were administered to mice bearing AR42J tumors. Tumor volume, body weight, complete blood count, and serum chemistry were monitored. Imaging was conducted in preclinical models to confirm the suitability of Pb-203 for SPECT. Validation of production methods was completed for submission to initiate trials. Initial human imaging was conducted in patients under appropriate laws to evaluate the biodistribution of the agent in humans.

Conference:

Presenting Author: Schultz M

Authors: Schultz M, Johnson F, Li M, Liu D, McDonald M,

Keywords: NET, neuroendocrine tumor, alpha therapy, Pb-212, Pb-203, SPECT,